(Q40412270)

20 September 2017

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients (English)

1 reference

20 September 2017

0 references

Krzysztof W Selmaj

6

0 references

Eva Havrdová

object named as

Eva Havrdova

5

0 references

Hans-Peter Hartung

4

object named as

Hans-Peter Hartung

1 reference

20 September 2017

1

Gavin Giovannoni

1 reference

20 September 2017

Jeffrey A Cohen

2

1 reference

20 September 2017

Alasdair J Coles

3

1 reference

20 September 2017

David H Margolin

7

1 reference

20 September 2017

Stephen L Lake

8

1 reference

20 September 2017

Susan M Kaup

9

1 reference

20 September 2017

Michael A Panzara

10

1 reference

20 September 2017

D Alastair S Compston

11

1 reference

20 September 2017

CARE-MS II Investigators

12

1 reference

20 September 2017

language of work or name

English

0 references

publication date

12 October 2016

1 reference

20 September 2017

1 reference

20 September 2017

87

1 reference

20 September 2017

19

1 reference

20 September 2017

1985-1992

1 reference

Alemtuzumab: the advantages and challenges of a novel therapy in MS.

20 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5109953

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5109953

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5109953

Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5109953

Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5109953

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5109953

The impact of increasing neurological disability of multiple sclerosis on health utilities: a systematic review of the literature

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5109953

Employment in multiple sclerosis. Exiting and re-entering the work force

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5109953

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5109953

Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5109953

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5109953

Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS.

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5109953

Development of a multiple sclerosis functional composite as a clinical trial outcome measure

25 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5109953

Power and sample size evaluation for the McNemar test with application to matched case-control studies

25 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5109953

Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

25 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5109953

Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity.

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5109953

Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation?

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5109953

Disease progression in multiple sclerosis: combining physicians' and patients' perspectives?

20 August 2018

1 reference

12 December 2020

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

12 December 2020

Clinical impact of 20% worsening on Timed 25-foot Walk and 9-hole Peg Test in multiple sclerosis

1 reference

12 December 2020

Contrast letter acuity as a visual component for the Multiple Sclerosis Functional Composite

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis

1 reference

12 December 2020

Assessing disability progression with the Multiple Sclerosis Functional Composite

1 reference

12 December 2020

Kurtzke scales revisited: the application of psychometric methods to clinical intuition

1 reference

12 December 2020

10.1212/WNL.0000000000003319

Identifiers

DOI

1 reference

20 September 2017

1 reference

20 September 2017

PubMed publication ID

27733571

1 reference